Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Eytan Rosenbloom

Interventional Pain Medicine Englewood Cliffs, NJ Medical Doctor

NPI 1922595842 CMS profile 11444337

910 Sylvan Ave, Ste 100, Englewood Cliffs, NJ 07632

Open in the dashboard

General payments

$3,261

25 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eytan Rosenbloom of Englewood Cliffs, NJ is reported in the CMS Open Payments database as having received $3,261 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $85 3
2024 General $116 4
2023 General $3,060 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eytan Rosenbloom
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Eytan Rosenbloom were reported at $85. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Eytan Rosenbloom Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $3,060 $671 $195–$1,915 $160
2024 $116 $684 $206–$1,837 $164
2025 $85 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Abbott Laboratories $2,775 14 payments
  2. Nevro Corp. $140 3 payments
  3. Curonix LLC $127 1 payment
  4. Medtronic, Inc. $115 2 payments
  5. SPR Therapeutics, Inc $53 3 payments
  6. DePuy Synthes Sales Inc. $32 1 payment
  7. Bioventus LLC $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Travel and Lodging $2,037 5 payments
  2. Food and Beverage $1,224 20 payments
Products named General payments · program years 2023–2025
  1. PROCLAIM $2,609 12 payments
  2. ETERNA $152 1 payment
  3. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $127 1 payment
  4. Senza $125 2 payments
  5. MINIMED 780G $115 2 payments
  6. SPRINT PNS System $53 3 payments
  7. HEALIX KNOTLESS PEEK $32 1 payment
  8. VAPR $32 1 payment
  9. CHIA PERCPASSER $32 1 payment
  10. GII $32 1 payment
  11. Other $80 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

563

Median for Interventional Pain Management: 1,220

Drug cost

$3,258

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 266 $1,436
Tizanidine Hcl Generic 74 $332
Cyclobenzaprine Hcl Generic 40 $300
Methylprednisolone Generic 40 $273
Pregabalin Generic 22 $205
Naproxen Generic 31 $189
Meloxicam Generic 45 $143
Diclofenac Sodium Generic 16 $135
Baclofen Generic 17 $131
Celecoxib Generic 12 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$91,811

Of which drugs: $2,404

Medicare patients

323

Average age 75

Services billed

1,221

212 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 29%
Osteoporosis 23%
Depression 21%
Chronic kidney disease 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record